Safety and efficacy of plasmid encoding p62/SQSTM1 in combination with CMF (Cyclophosphamide + Methotrexate + Fluorouracil) chemotherapy in patients with metastatic triple-negative breast cancer
Latest Information Update: 08 Mar 2023
At a glance
- Drugs P62-cancer-dna-vaccine CureLab Oncology (Primary) ; Cyclophosphamide; Fluorouracil; Methotrexate
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Mar 2023 According to a CureLab media release, following impressive clinical data presented at the European Society for Medical Oncology Congress in Paris, the funds will enable CureLab Oncology to ramp up toward this FDA-monitored clinical trial in 2023.
- 24 Nov 2021 New trial record